Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Gabriel Tremblay, Tim Holbrook, Gary Milligan, Corey L Pelletier & Petra Rietschel. (2016) Matching-adjusted indirect treatment comparison in patients with radioiodine-refractory differentiated thyroid cancer. Comparative Effectiveness Research 6, pages 13-21.
Read now
Read now
Articles from other publishers (16)
Ghazal G Alsisi, Mohammed H Alsisi, Alauldin K Alhowaish & Wardah S Alshammari. (2022) Erythema Dyschromicum Perstans After Adalimumab Treatment. Cureus.
Crossref
Crossref
Jean-Guillaume Letarouilly, Benoît Flachaire, Céline Labadie, Maéva Kyheng, Nicolas Cohen, Jérémie Sellam, Pascal Richette, Philippe Dieude, Pascal Claudepierre, Bruno Fautrel, Eric Houvenagel, Chi Duc Nguyen, Marie-Hélène Guyot, Nicolas Segaud, Laurent Marguerie, Xavier Deprez, Jean-Hugues Salmon, Guy Baudens, Corinne Miceli-Richard, Elisabeth Gervais, Isabelle Chary-Valckenaere, Pierre Lafforgue, Peggy Philippe, Damien Loeuille, Christophe Richez, Florence Tubach, Thao Pham & René-Marc Flipo. (2021) Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison. Rheumatology 60:6, pages 2773-2782.
Crossref
Crossref
Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair, Wolf-Henning Boehncke & Christopher Ritchlin. (2021) Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology 60:5, pages 2109-2121.
Crossref
Crossref
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert, Paul Emery, Sreekumar G Pillai & Philip S Helliwell. (2020) A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Annals of the Rheumatic Diseases 79:1, pages 123-131.
Crossref
Crossref
Ernest Choy, Xenofon Baraliakos, Frank Behrens, Salvatore D’Angelo, Kurt de Vlam, Bruce W. Kirkham, Mikkel Østergaard, Georg A. Schett, Michael Rissler, Kamel Chaouche-Teyara & Chiara Perella. (2019) The need for comparative data in spondyloarthritis. Arthritis Research & Therapy 21:1.
Crossref
Crossref
S. Cazzaniga, F. Anzengruber, M. Augustin, W.H. Boehncke, L. Borradori, C. Conrad, A. Cozzio, V. Djamei, L.E. French, M. Gilliet, P. Häusermann, K. Heidemeyer, P. Itin, A.G.A. Kolios, E. Laffitte, J.‐T. Maul, C. Mainetti, L. Naldi, A.A. Navarini, S.J. Rustenbach, D. Simon, C. Sorbe, M. Streit & N. Yawalkar. (2019) Linkage between patients’ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. Journal of the European Academy of Dermatology and Venereology 33:12, pages 2313-2318.
Crossref
Crossref
A.P. Bewley, N.H. Shear, P.G. Calzavara‐Pinton, J.B. Hansen, M.E. Nyeland & J. Signorovitch. (2019) Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching‐adjusted indirect comparison. Journal of the European Academy of Dermatology and Venereology 33:6, pages 1107-1115.
Crossref
Crossref
Vibeke Strand, Iain McInnes, Philip Mease, Peter Nash, Howard Thom, Chrysostomos KalyvasMatthias Hunger, Kunal Gandhi, Luminita Pricop, Steffen Jugl & Ernest Choy. (2019) Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. Journal of Comparative Effectiveness Research 8:7, pages 497-510.
Crossref
Crossref
Irina Proskorovsky, Agnes Benedict, Sylvie Negrier, Danielle Bargo, Rickard Sandin, Krishnan Ramaswamy, Jigar Desai, Joseph C. Cappelleri & James Larkin. (2018) Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses. BMC Cancer 18:1.
Crossref
Crossref
Peter Nash, Iain B. McInnes, Philip J. Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu & Steffen M. Jugl. (2018) Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. Rheumatology and Therapy 5:1, pages 99-122.
Crossref
Crossref
Tzu-Hao Li, Hsien-Tzung Liao, Yi-Fan Huang, Yu-Chuan Shen, Yao-Chang Chiu, Wei-Sheng Chen, Ming-Han Chen, Chang-Youh Tsai & Deh-Ming Chang. (2018) The current status and unmet needs in the management of psoriatic arthritis: Viewpoint from physicians in Taiwan. Journal of the Formosan Medical Association 117:5, pages 404-412.
Crossref
Crossref
Lucia Sara D’Angiolella, Paolo Angelo Cortesi, Alessandra Lafranconi, Mariangela Micale, Sveva Mangano, Giancarlo Cesana & Lorenzo Giovanni Mantovani. (2018) Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. PharmacoEconomics 36:5, pages 567-589.
Crossref
Crossref
Elyse Swallow, Anna Fang, James Signorovitch, Jonathan Plumb & Simon Borghs. (2017) Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?. CNS Drugs 31:10, pages 899-910.
Crossref
Crossref
Steven Sherman, Billy Amzal, Emiliano Calvo, Xufang Wang, Jinhee Park, Zhimei Liu, Chinjune Lin & Roman Casciano. (2015) An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed. Clinical Therapeutics 37:11, pages 2552-2559.
Crossref
Crossref
W.H. Boehncke, A. Qureshi, J.F. Merola, D. Thaçi, G.G. Krueger, J. Walsh, N. Kim & A.B. Gottlieb. (2014) Diagnosing and treating psoriatic arthritis: an update. British Journal of Dermatology 170:4, pages 772-786.
Crossref
Crossref
Shi Hu, Shuaiyi Liang, Huaizu Guo, Dapeng Zhang, Hui Li, Xiaoze Wang, Weili Yang, Weizhu Qian, Sheng Hou, Hao Wang, Yajun Guo & Zhiyong Lou. (2013) Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View. Journal of Biological Chemistry 288:38, pages 27059-27067.
Crossref
Crossref